drugset / Trial / NCT04384588
COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID)
Phase 2/3
Unknown
100 enrolled
Fundacion Arturo Lopez Perez
Bolsa de Santiago · collabConfederación de la Producción y del Comercio (CPC) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
COVID-19 infection has spread worldwide causing several deaths in few months Convalescent Plasma from COVID 19 donors has shown huge activity in small series from Chinese patients and currently many centers from USA and the European Union are assessing its use looking to avoid mortality and prolonged hospitalizations COVID-19-related
Timeline
- Start
- 2020-04-07
- Primary completion
- 2021-04-06
- Completion
- 2021-04-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Convalescent Plasma from COVID-19 donors | Unknown | — | — |